Halia Therapeutics
Halia Therapeutics, Inc.
Halia Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and neurological diseases. The company's research targets the NLRP3 inflammasome, a key driver of chronic inflammation implicated in conditions like Alzheimer's, Parkinson's, and various autoimmune disorders. Halia aims to resolve chronic inflammation and mitigate damage from overactive immune responses through its pipeline of investigational drugs.
Products & Team
HT-6184 (Ofirnoflast)
HT-6184 is a first-in-class, orally bioavailable, small molecule inhibitor of the NLRP3/NEK7 inflammasome. It is currently advancing through Phase 2 clinical trials for multiple indications, including lower-risk myelodysplastic syndromes (LR-MDS) and post-procedural inflammatory pain.
HT-6184 addresses the root cause of various chronic diseases by directly inhibiting the NLRP3 inflammasome, a central pathway of the innate immune system responsible for pathological inflammation. This offers a targeted therapeutic strategy for conditions that currently lack effective treatments.
Patients suffer from debilitating symptoms and disease progression caused by chronic inflammation, for which existing therapies may be inadequate or have significant side effects. Halia's approach targets the underlying inflammatory mechanism to provide a more fundamental treatment.